HyperRAB is considered relevant in situations involving acute, high-risk exposure to the rabies virus, helping to address the potential for a catastrophic viral infection. This agent is commonly used as part of the regimen for individuals who have not been previously vaccinated.

The primary therapeutic domain is Emergency Post-Exposure Immunoprophylaxis. It is applied in clinical settings that involve acute exposure, such as following bite trauma, deep scratches, or when animal saliva contaminates broken skin. HyperRAB provides support that helps ease the overall symptom burden by providing supportive immune assistance, which may assist with managing the risk of developing the severe neurological symptoms associated with clinical rabies.

This agent is commonly used across conditions presenting with acute exposure in unvaccinated individuals, including both children and adults. The benefit contributes to providing supportive immune assistance and helps improve day-to-day comfort during symptomatic periods, supporting the patient during this period while the body's active immune response from the concurrent vaccine is allowed to develop.

“This agent is relevant for managing symptoms that interfere with daily comfort by supporting the patient during a high-risk phase.”

Quick Fact	Symptomatic Support
Primary Domain	Viral Zoonotic Disease Prevention
Targeted Support	Supportive immunity for acute viral exposure
Use Scenario	Applied in clinical settings marked by temporary physiological imbalance
Key Benefit	Contributes to managing the risk of intense manifestations

Who can and cannot use HyperRAB?

Eligibility to use HyperRAB (Rabies immune globulin) is determined by regulatory criteria related to a patient's existing immune status and specific medical conditions. The medicine is indicated exclusively for Post-Exposure Prophylaxis (PEP).

---

Eligibility Status

• Permitted Use: HyperRAB is authorized for use in individuals who have not been previously immunized against rabies. The official labeling confirms it is permitted for use across the pediatric population. Use in pregnant and lactating women is also permitted when PEP is deemed necessary, given the life-threatening nature of rabies exposure.
• Not Indicated: The product is not indicated for individuals who have already received a complete course of rabies vaccination and possess adequate antibody titers. Administration is also not recommended after the seventh day following the first dose of the rabies vaccine.

---

Contraindicated and Conditional Use

Use is contraindicated in patients with a history of systemic allergic reactions to human immune globulin preparations. It is also absolutely prohibited for patients with a documented selective immunoglobulin A (IgA) deficiency who have anti-IgA antibodies.

Patients with bleeding disorders or thrombocytopenia may receive the product, but require special caution due to the risk of hematoma associated with intramuscular injection. No specific restrictions are documented for patients with hepatic or renal impairment.

Interactions with other medicines and products

Interaction scope

The interaction profile of HyperRAB is based on its function as an immune globulin, focusing on its ability to interfere with the immune response to other biological products. No clinically significant pharmacokinetic (metabolic or transporter) interactions, or interactions with food, alcohol, or herbal products are documented in official regulatory labeling.

Property	Classification / Restriction
Medicinal product categories with documented interactions	Live attenuated virus vaccines
Specific interacting medicines (if explicitly listed)	Rabies Vaccine, Measles Vaccine
Mechanistic basis of interactions	Pharmacodynamic interference (neutralizing antibodies suppress active immune response to vaccine antigens)
Timing-based interaction rules	Measles vaccine administration must be deferred for a mandatory four months; other live attenuated vaccines may require deferral for at least three months.
Interaction-related restrictions	Do not administer HyperRAB and the Rabies Vaccine in the same syringe or the same anatomical site.

Interaction classifications (high-level)

Property	Classification
Interaction severity classification	Clinically Significant Pharmacodynamic Interaction / Contraindicated Administration Procedure
Regulatory basis	US Food and Drug Administration (FDA) Prescribing Information
Interaction-context constraints	Administration must avoid local mixing of immune globulin and vaccine antigen; subsequent live vaccine administration requires mandatory deferral.

Resulting interaction structure

Official regulatory documents detail two primary interaction concerns. First, the co-administration of the Rabies Immune Globulin and the Rabies Vaccine in the same syringe or the same anatomical site is prohibited, as this procedural interaction risks neutralizing the vaccine at the local level. Second, the administration of HyperRAB may interfere with the development of active immunity from live attenuated virus vaccines, such as the Measles Vaccine, resulting in a mandatory deferral period of four months for their subsequent administration. Additional doses of the immune globulin are also restricted once the vaccine series is underway, as they may suppress the immune response.

HyperRAB is a preparation of purified human mathbfIgG antibodies specific to the Rabies lyssavirus glycoprotein, which constitutes the virion surface antigen. The mathbfIgG components function as non-competitive antagonists by targeting and binding to the rabies virus particles at the site of administration, which is the locally exposed tissue.

Molecular Mechanism

This antibody-virus interaction leads to the steric hindrance and neutralization of the virions. By forming mathbfIgG-virus complexes, the molecular ability of the virus to attach to and enter host muscle cells and subsequent peripheral nerve endings is blocked. This binding is immediate upon local tissue infiltration, establishing a high concentration of neutralizing antibodies at the primary exposure site.

System-Level Consequence

The local neutralization of the virus interrupts the initial stages of viral replication and the subsequent retrograde axonal transport toward the central nervous system. This systemic physiological modulation is a form of passive immunization, providing instantaneous humoral immunity until the host's active immune response, triggered by the concurrently administered vaccine, produces its own neutralizing antibodies.

HyperRAB is a sterile solution for injection that is administered as a critical single-dose component of rabies post-exposure prophylaxis (PEP).

Administration Route and Method

The dosage must be physically administered using a split route. The majority of the calculated dose is delivered via local infiltration, meaning it is injected directly into and around the wound site(s) to target the potential point of infection. Any remaining volume that cannot be physically infiltrated is administered via a separate intramuscular (IM) injection at an anatomical site distant from the vaccine site. This product must not be administered intravenously.

Dosing and Scheduling

The standard regimen for all age groups is a single application of 20 International Units per kilogram (20 IU/kg) of actual body weight. This exact dose must not be exceeded. The agent is intended for immediate administration, preferably concurrently with the first dose of the rabies vaccine (often referred to as Day 0). HyperRAB is not indicated for administration beyond seven days after the active rabies vaccine series has begun.

Procedural Constraints

To maintain the integrity of the treatment protocol, HyperRAB and the rabies vaccine must not be mixed in the same syringe. If dilution is necessary to ensure thorough infiltration of extensive wounds, only an equal volume of Dextrose 5% in Water (D5W) should be used, following strict preparation instructions.

Research Evidence / Overview of Studies for HyperRAB

---

Evidence for Use in Rabies Post-Exposure Prophylaxis (PEP)

The use of Human Rabies Immune Globulin (HRIG), including HyperRAB, was studied as part of an immediate, passive immunization regimen in patients following a potential exposure to the rabies virus. The main research design includes randomized, double-blind, non-inferiority trials. These are studies where researchers compared the immunological characteristics of HyperRAB against other licensed HRIG products already in use.

Researchers focused primarily on immunological outcomes rather than clinical disease outcomes, as direct prevention trials are not typically feasible. The central measurement in these studies is the Rabies Virus Neutralizing Antibody (RVNA) titer, which is the lab marker recognized in the research community as the correlate of protection. Research described how the proportion of participants who attained this protective antibody level (seroconversion) was observed in the study groups. The evidence contributes to understanding the expected antibody response patterns when the product is given as part of the full post-exposure regimen, along with a rabies vaccine.

---

Comparing Rabies Immune Globulin Preparations

This area will outline the evidence derived from comparative clinical trials that examined HyperRAB in relation to other Human Rabies Immune Globulin (HRIG) products. These studies focused on the pharmacokinetic (PK) measures, which involve tracking how the body absorbs and processes the administered antibodies. Studies described patterns observed during the research period, where the goal was to evaluate whether the immunological response achieved by HyperRAB was consistent with that of other established products.

---

What Is Still Uncertain or Under Investigation

A key limitation of the research is that direct human trials proving prevention of clinical rabies disease are not conducted due to ethical constraints. Therefore, the research does not include direct data on disease prevention, which is instead assessed by measuring the antibody titer, which is an accepted marker. Furthermore, research highlights what is known — and what is still uncertain — regarding the administration of the product within the parameters of the research. Specifically, studies observed patterns related to the risk of partial suppression of the active immune response to the concurrent vaccine if the dose of the immune globulin is outside the range evaluated in the research.

Key Studies & References

1. Rabies Immune Globulin (Human) HyperRAB® S/D - Full Prescribing Information (DailyMed)

Common questions about HyperRAB (FAQ)

Q: How long do the effects of HyperRAB last in the body?

Official information indicates that the detectable neutralizing antibodies provided by HyperRAB persisted throughout the 21-day period examined in related studies. This rapid, passive protection is intended to provide immediate support until the body's active immune response, triggered by the rabies vaccine, can develop its own long-term protection.

Q: Can children or infants be given HyperRAB?

HyperRAB is authorized for use across all age groups, including children, as part of the necessary post-exposure treatment. However, official regulatory documents note that the safety and effectiveness of the product have not been established specifically in pediatric populations through clinical trials.

Q: Is HyperRAB a common treatment, or is it only used in severe cases?

According to official product information, HyperRAB is indicated for post-exposure prophylaxis (PEP) in all persons suspected of rabies exposure who have not been previously immunized. The product is considered an essential component of PEP and is not reserved solely for cases classified as severe.

Q: Is the research evidence for HyperRAB strong?

Research studies on the product focused on immunological characteristics, specifically tracking the presence of neutralizing antibodies (the marker for protection accepted in the research community). The evidence examined how the product provides a reproducible passive transfer of these antibodies when administered as part of the full post-exposure regimen.

Q: Does HyperRAB make you feel sick immediately after getting it?

Clinical trial data lists common systemic adverse reactions such as headache, abdominal pain, and diarrhea. The official product information does not specify the precise timing (immediate or delayed) of when these general systemic reactions may begin.

Q: How do regulatory agencies like the FDA classify the safety of HyperRAB?

Because HyperRAB is derived from pooled human plasma, its official labeling documents a theoretical risk of transmitting infectious agents, including certain viruses or the Creutzfeldt-Jakob Disease (CJD) agent. Regulatory information also notes that patients with a specific immune deficiency, known as IgA deficiency, are noted to be at an increased risk of developing severe hypersensitivity reactions.

Q: Has there been recent research on HyperRAB effectiveness in different populations?

Regulatory documents note that the safety and effectiveness of HyperRAB have not been established in specific groups, including pediatric (children) or geriatric (elderly) populations. Official information reflects that this limitation is a factor in treatment consideration.

Q: Does HyperRAB contain live virus?

No, HyperRAB is a sterile solution made up of purified IgG antibodies, and it does not contain a live virus. The manufacturing process involves specific steps, such as heat treatment and nanofiltration, designed to inactivate and remove potential infectious agents.

Q: Can HyperRAB cause a delayed reaction?

While the regulatory documents list potential adverse reactions like mild temperature elevations or a skin rash, the official prescribing information does not classify the timing of these effects as either 'immediate' or 'delayed.' The specific time of onset for side effects is not fully defined in the regulatory documents.

Q: Does HyperRAB cause a fever?

Official prescribing information indicates that mild temperature elevations may be observed at times as a potential adverse reaction after administration. Fever is a general systemic reaction that is sometimes reported.

Q: Are there any religious or dietary concerns regarding the ingredients of HyperRAB?

HyperRAB is a biological product derived from pooled human plasma. Official documents confirm it contains no preservatives and is not made with natural rubber latex. Specific religious or dietary concerns related to human-derived products are generally not addressed in the official regulatory documentation.

Q: Is it safe to receive HyperRAB if I am taking steroids?

The official label for HyperRAB does not explicitly address the use of steroids. However, because steroids are an immunosuppressive agent, the regulatory guidance for the concurrently administered rabies vaccine reflects the concern regarding the use of these agents during post-exposure prophylaxis unless medically essential.

Q: Why are there different types of Rabies Immune Globulin products available?

Official documents note that HyperRAB is manufactured as a higher concentration product compared to other formulations of Human Rabies Immune Globulin. This concentration difference may result in a lower total volume administered, which has implications for local infiltration into wound sites.

Q: Why is it important to clean the wound before receiving HyperRAB?

The recommended post-exposure treatment regimen specifies that all bite wounds and scratches should be thoroughly washed and flushed immediately with soap and water for a period of about 15 minutes. This procedural step is documented as occurring before HyperRAB is administered.

HyperRAB (Rabies Immune Globulin [Human]) must be stored according to specific temperature guidelines to maintain its effectiveness. It should be kept refrigerated at a temperature between 2°C and 8°C (36°F and 46°F). It is critical not to freeze the solution; any product that has been frozen must not be used and should be discarded.

Alternatively, HyperRAB may be stored at room temperature, not exceeding 25°C (77°F), for a single period of up to six months, provided this is done before the product's overall expiration date. After being stored at room temperature, the product must be used or properly discarded and should not be returned to refrigeration. The solution should be visually inspected for particulate matter or discoloration before use; if it appears tampered with or compromised, it must be discarded. Any unused portion of the product must be discarded in accordance with local biological waste disposal procedures.